{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:32:30Z","timestamp":1791981150321,"version":"4.4.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032091","name":"Royal Free Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bone.2026.117796","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:33:51Z","timestamp":1768494831000},"page":"117796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Osteoblastic cell responses to zoledronate treatment in-vitro: A systematic review"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-0629","authenticated-orcid":false,"given":"Maria","family":"Florez-Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana-Monica","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Shakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Jell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.117796_b1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers","year":"2020","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2026.117796_b2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b3","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofacial Surg. Clin. North Am."},{"issue":"7","key":"10.1016\/j.bone.2026.117796_b5","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s00784-018-2349-6","article-title":"Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro","volume":"22","author":"Jung","year":"2018","journal-title":"Clin. Oral Investig."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2026.117796_b7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00204-021-03220-y","article-title":"Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw","volume":"96","author":"Srivichit","year":"2022","journal-title":"Arch. Toxicol."},{"issue":"7","key":"10.1016\/j.bone.2026.117796_b9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-012-1216-7","article-title":"Bisphosphonates: effects on osteoblast","volume":"68","author":"Maruotti","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2026.117796_b10","series-title":"Encyclopedia of Bone Biology","first-page":"565","article-title":"Bisphosphonates and bone cells\u2014Molecular mechanisms","author":"Munoz","year":"2020"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","article-title":"Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells","volume":"42","author":"Coxon","year":"2008","journal-title":"BONE"},{"key":"10.1016\/j.bone.2026.117796_b13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41533-020-0162-6","article-title":"A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England","volume":"30","author":"Chalitsios","year":"2020","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"10.1016\/j.bone.2026.117796_b14","article-title":"The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence","volume":"14","author":"Liu","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-p) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"10.1016\/j.bone.2026.117796_b16","article-title":"Osteoblastic cell responses to zoledronate treatment in-vitro: a systematic review","author":"Florez-Martin","year":"2024","journal-title":"OSF"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.toxlet.2009.05.013","article-title":"\u201cToxRTool\u201d, a new tool to assess the reliability of toxicological data","volume":"189","author":"Schneider","year":"2009","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejphar.2008.10.031","article-title":"Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells","volume":"600","author":"Virginia Gangoiti","year":"2008","journal-title":"European J. Pharmacology"},{"key":"10.1016\/j.bone.2026.117796_b20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.freeradbiomed.2023.06.022","article-title":"Menaquinone-4 prevents medication-related osteonecrosis of the jaw through the SIRT1 signaling-mediated inhibition of cellular metabolic stresses-induced osteoblast apoptosis","volume":"206","author":"Cui","year":"2023","journal-title":"Free Radical Biology Medicine"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3892\/ol.2012.723","article-title":"Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells","volume":"4","author":"Chang","year":"2012","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000351194","article-title":"Zoledronic acid inhibits human osteoblast activities","volume":"59","author":"Basso","year":"2013","journal-title":"Gerontologia"},{"issue":"27","key":"10.1016\/j.bone.2026.117796_b23","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Current Pharmaceutical Design"},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b24","first-page":"707","article-title":"Effect of dexamethasone on the growth and differentiation of osteoblast-like cells derived from the human alveolar bone","volume":"17","author":"Tabassum","year":"2022","journal-title":"J. Taibah Univ. Med. Sci."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7150\/ijms.32612","article-title":"Zoledronate induces cell cycle arrest and differentiation by upregulating p21 in mouse MC3t3-E1 preosteoblasts","volume":"16","author":"Huang","year":"2019","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1186\/s12903-024-04906-2","article-title":"Increased bone mass but delayed mineralization: in vivo and in vitro study for zoledronate in bone regeneration","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Oral. Health"},{"issue":"10","key":"10.1016\/j.bone.2026.117796_b27","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1177\/0300060518788987","article-title":"Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials","volume":"46","author":"Holtmann","year":"2018","journal-title":"J. Int. Med. Res."},{"issue":"11","key":"10.1016\/j.bone.2026.117796_b28","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1359\/jbmr.2002.17.11.1997","article-title":"Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells","volume":"17","author":"Parhami","year":"2002","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2026.117796_b29","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jor.20437","article-title":"Oxysterols enhance osteoblast differentiation in vitro and bone healing in vivo","volume":"25","author":"Aghaloo","year":"2007","journal-title":"J. Orthop. Res.: Off. Publ. Orthop. Res. Soc."},{"issue":"7","key":"10.1016\/j.bone.2026.117796_b30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/labinvest.2016.51","article-title":"Apolipoprotein A-1 regulates osteoblast and lipoblast precursor cells in mice","volume":"96","author":"Blair","year":"2016","journal-title":"Lab. Invest."},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b31","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/jbmr.3390","article-title":"Osteoblast-like MC3t3-E1 cells prefer glycolysis for ATP production but adipocyte-like 3T3-L1 cells prefer oxidative phosphorylation","volume":"33","author":"Guntur","year":"2018","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res."},{"issue":"16","key":"10.1016\/j.bone.2026.117796_b32","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.3390\/ijms241612716","article-title":"Practical use of immortalized cells in medicine: Current advances and future perspectives","volume":"24","author":"Voloshin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","article-title":"The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors","volume":"99","author":"Scharenberg","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/cells9051141","article-title":"The role of extracellular vesicles in the Hallmarks of cancer and drug resistance","volume":"9","author":"Xavier","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00774-016-0806-3","article-title":"Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis","volume":"35","author":"Shiraki","year":"2017","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b36","doi-asserted-by":"crossref","first-page":"24799","DOI":"10.1038\/srep24799","article-title":"Cross-tissue analysis of gene and protein expression in normal and cancer tissues","volume":"6","author":"Kosti","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2026.117796_b37","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144855","article-title":"Alkaline phosphatase: Structure, expression and its function in bone mineralization","volume":"754","author":"Vimalraj","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.bone.2026.117796_b38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jct.2016.02.005","article-title":"Thermodynamic study of the interaction between calcium and zoledronic acid by calorimetry","volume":"97","author":"Mostefa Side Larbi","year":"2016","journal-title":"J. Chem. Thermodyn."},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0012-1606(83)90232-4","article-title":"Effect of experimentally induced calcium deficiency on the developmental expression of collagen types in chick embryonic skeleton","volume":"100","author":"Tuan","year":"1983","journal-title":"Dev. Biol."},{"issue":"15","key":"10.1016\/j.bone.2026.117796_b40","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100363","article-title":"Calcium\u2013collagen coupling is vital for biomineralization schedule","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.bone.2026.117796_b41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41578-020-0213-1","article-title":"Collagen: quantification, biomechanics, and role of minor subtypes in cartilage","volume":"5","author":"Bielajew","year":"2020","journal-title":"Nat. Rev. Mater."},{"issue":"10","key":"10.1016\/j.bone.2026.117796_b42","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1038\/cddis.2013.406","article-title":"Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways","volume":"4","author":"Bruzzese","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bone.2026.117796_b43","doi-asserted-by":"crossref","DOI":"10.1038\/srep44245","article-title":"Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells","volume":"7","author":"Tai","year":"2017","journal-title":"SCIENTIFIC REPORTS"},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101207","article-title":"Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83","volume":"9","author":"Ge","year":"2014","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.bone.2026.117796_b45","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b46","first-page":"2893","article-title":"Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2026.117796_b47","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.00336","article-title":"Primary Human Osteoblasts Cultured in a 3D Microenvironment Create a Unique Representative Model of Their Differentiation Into Osteocytes","volume":"8","author":"Nasello","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bone.2026.117796_b48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/1756-0500-4-410","article-title":"Internal control genes for quantitative RT-PCR expression analysis in mouse osteoblasts, osteoclasts and macrophages","volume":"4","author":"Stephens","year":"2011","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.bone.2026.117796_b49","series-title":"Assay Guidance Manual","article-title":"Cell Viability Assays","author":"Riss","year":"2004"},{"issue":"23","key":"10.1016\/j.bone.2026.117796_b50","doi-asserted-by":"crossref","first-page":"12827","DOI":"10.3390\/ijms222312827","article-title":"The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis","volume":"22","author":"Ghasemi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2026.117796_b51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13104-015-1000-8","article-title":"Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays","volume":"8","author":"van Tonder","year":"2015","journal-title":"BMC Res. Notes"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b52","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1038\/s41598-022-18067-1","article-title":"Hypoxia mimetics restore bone biomineralisation in hyperglycaemic environments","volume":"12","author":"Rezaei","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bone.2026.117796_b53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00784-015-1528-y","article-title":"PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells","volume":"20","author":"Anitua","year":"2016","journal-title":"Clinical Oral Investigations"},{"key":"10.1016\/j.bone.2026.117796_b54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.archoralbio.2018.06.018","article-title":"Epigallocatechin-3-gallate reduces damage to osteoblast-like cells treated with Zoledronic acid","volume":"94","author":"Pons-Fuster Lopez","year":"2018","journal-title":"Archives Oral Biology"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcb.21983","article-title":"Inhibition of osteoblast function in vitro by aminobisphosphonates","volume":"106","author":"Orriss","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b56","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/jbm.a.34937","article-title":"A phenotypic comparison of osteoblast cell lines versus human primary osteoblasts for biomaterials testing","volume":"102","author":"Czekanska","year":"2014","journal-title":"J. Biomed. Mater. Res. Part A"},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b57","first-page":"3743","article-title":"Characterization of Osteosarcoma Cell Lines MG-63, Saos-2 and U-2 OS in Comparison to Human Osteoblasts","volume":"24","author":"Pautke","year":"2004","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mce.2003.06.002","article-title":"Cell lines and primary cell cultures in the study of bone cell biology","volume":"228","author":"Kartsogiannis","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b59","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11033-018-4532-x","article-title":"The effects of bisphosphonates on osteonecrosis of jaw bone: a stem cell perspective","volume":"46","author":"Abdik","year":"2019","journal-title":"Mol. Biol. Rep."},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b60","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1016\/j.jcms.2011.10.024","article-title":"The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells","volume":"40","author":"Acil","year":"2012","journal-title":"J. Cranio-Maxillofacial Surgery"},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcms.2017.12.015","article-title":"Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells","volume":"46","author":"Acil","year":"2018","journal-title":"J. Cranio-Maxillofacial Surgery"},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b62","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ajoms.2022.01.007","article-title":"Zoledronate and lipopolysaccharide suppress osteoblast differentiation through downregulating phosphorylation of Smad in pre-osteoblastic MC3t3-E1 cells","volume":"34","author":"Amamoto","year":"2022","journal-title":"J. Oral Maxillofacial Surgery Medicine Pathology"},{"key":"10.1016\/j.bone.2026.117796_b63","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1590\/S1676-24442013000500011","article-title":"Inhibition of osteoblast activity by zoledronic acid","volume":"49","author":"Basso","year":"2013","journal-title":"J. Bras. de Patol. E Med. Lab."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijom.2012.03.026","article-title":"Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells","volume":"42","author":"Bayram","year":"2013","journal-title":"International J. Oral Maxillofacial Surgery"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b65","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2006.10.004","article-title":"Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells","volume":"250","author":"Benassi","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bone.2026.117796_b66","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4597321","article-title":"Beneficial effects of concentrated growth factors and resveratrol on human osteoblasts in vitro treated with bisphosphonates","volume":"2018","author":"Borsani","year":"2018","journal-title":"Biomed Research International"},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b67","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jcms.2017.04.006","article-title":"Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts","volume":"45","author":"Camacho-Alonso","year":"2017","journal-title":"J. Cranio-Maxillofacial Surgery"},{"key":"10.1016\/j.bone.2026.117796_b68","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2023.105703","article-title":"Naringenin and proanthocyanidins pre-treatment decreases synthesis and activity of gelatinases induced by zoledronic acid in a dental implant surface in vitro model","volume":"151","author":"Cardoso","year":"2023","journal-title":"Arch. Oral. Biol."},{"issue":"7","key":"10.1016\/j.bone.2026.117796_b69","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/JPER.18-0644","article-title":"Histatin-1 counteracts the cytotoxic and antimigratory effects of zoledronic acid in endothelial and osteoblast-like cells","volume":"90","author":"Castro","year":"2019","journal-title":"J. Periodontology"},{"key":"10.1016\/j.bone.2026.117796_b70","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/BJ20040380","article-title":"Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition","volume":"384","author":"Chaplet","year":"2004","journal-title":"Biochemical J."},{"key":"10.1016\/j.bone.2026.117796_b71","article-title":"Geranylgeraniol restores zoledronic acid-induced efferocytosis inhibition in bisphosphonate-related osteonecrosis of the jaw","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Cell Dev. Biology"},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b72","first-page":"873","article-title":"Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures","volume":"28","author":"Corrado","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"11","key":"10.1016\/j.bone.2026.117796_b73","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202370036","article-title":"Polymeric nanoformulation of zoledronic acid rescues osteoblasts from the harmful effect of its native form: An in vitro investigation of cytotoxic potential on osteoblasts and osteosarcoma cells","volume":"23","author":"Dash","year":"2023","journal-title":"Macromol. Biosci."},{"issue":"12","key":"10.1016\/j.bone.2026.117796_b74","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1535-7163.MCT-07-0546","article-title":"Zoledronic acid inhibits osteosarcoma growth in an orthotopic model","volume":"6","author":"Dass","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b75","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/j.jcms.2012.01.028","article-title":"Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo","volume":"40","author":"Draenert","year":"2012","journal-title":"J. Cranio-Maxillofacial Surg."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b76","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bone.2009.01.009","article-title":"Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation","volume":"44","author":"Ebert","year":"2009","journal-title":"BONE"},{"key":"10.1016\/j.bone.2026.117796_b77","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4351327","article-title":"Geranylgeraniol (GGOH) as a mevalonate pathway activator in the rescue of bone cells treated with zoledronic acid: An in vitro study","volume":"2019","author":"Fliefel","year":"2019","journal-title":"Stem Cells International"},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b78","first-page":"4585","article-title":"Zoledronic acid regulates osteoblast differentiation via the mTORC1 signaling pathway","volume":"11","author":"Gao","year":"2018","journal-title":"International J. Clinical Experimental Medicine"},{"key":"10.1016\/j.bone.2026.117796_b79","article-title":"Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs osteogenic activity","volume":"7","author":"Gong","year":"2017","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b80","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/jbm.a.30950","article-title":"The effect of zoledronic acid incorporated in a poly(d,l-lactide) implant coating on osteoblasts in vitro","volume":"80","author":"Greiner","year":"2007","journal-title":"J. Biomedical Materials Research Part A"},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jormas.2023.101479","article-title":"Dose-dependent effects of zoledronic acid on the osteogenic differentiation of human bone marrow stem cells (hBMSCs)","volume":"124","author":"Hadad","year":"2023","journal-title":"J. Stomatol. Oral Maxillofacial Surg."},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b82","first-page":"90","article-title":"Zoledrinic acid induces steoblastic differentiation of mesenchymal stem cells without change in hypomethylation status of OSTERIX promoter","volume":"14","author":"Hagh","year":"2012","journal-title":"Cell J."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"BONE"},{"issue":"10","key":"10.1016\/j.bone.2026.117796_b84","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/jop.12442","article-title":"The enhancing effect of a laser photochemotherapy with cisplatin or zolendronic acid in primary human osteoblasts and osteosarcoma cells in vitro","volume":"45","author":"Heymann","year":"2016","journal-title":"J. Oral Pathology Medicine"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b86","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3892\/mmr.2015.4627","article-title":"Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro","volume":"13","author":"Huang","year":"2016","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.bone.2026.117796_b87","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0818-5","article-title":"The effects of zoledronate on the survival and function of human osteoblast-like cells","volume":"16","author":"Huang","year":"2015","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b88","doi-asserted-by":"crossref","first-page":"154","DOI":"10.31925\/farmacia.2019.1.21","article-title":"Effects of zoledronic acid on osteoblast proliferation and IGF-1 expressions in rats in vitro","volume":"67","author":"Huang","year":"2019","journal-title":"Farm\u00e1cia"},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b89","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.3892\/mmr.2016.5669","article-title":"Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment","volume":"14","author":"Hu","year":"2016","journal-title":"Molecular Medicine Reports"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/scd.2016.0173","article-title":"Pretreatment with bisphosphonate enhances osteogenesis of bone marrow mesenchymal stem cells","volume":"26","author":"Hu","year":"2017","journal-title":"Stem Cells Development"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b91","first-page":"285","article-title":"Zoledronate-induced s phase arrest and apoptosis accompanied by DNA damage and activation of the ATM\/Chk1\/cdc25 pathway in human osteosarcoma cells","volume":"31","author":"Iguchi","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b92","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cyto.2014.10.025","article-title":"The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells","volume":"71","author":"Ishtiaq","year":"2015","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.bone.2026.117796_b93","doi-asserted-by":"crossref","first-page":"359","DOI":"10.7150\/ijms.22627","article-title":"Bisphosphonate modulation of the gene expression of different markers involved in osteoblast physiology: Possible implications in bisphosphonate-related osteonecrosis of the jaw","volume":"15","author":"Javier Manzano-Moreno","year":"2018","journal-title":"International J. Medical Sciences"},{"issue":"6","key":"10.1016\/j.bone.2026.117796_b94","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jcms.2015.04.012","article-title":"Cytoprotective effects of melatonin on zoledronic acid-treated human mesenchymal stem cells in vitro","volume":"43","author":"Javier Rodriguez-Lozano","year":"2015","journal-title":"J. Cranio-Maxillofacial Surgery"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b95","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-013-2613-z","article-title":"Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells","volume":"140","author":"Kaiser","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.oooo.2016.08.010","article-title":"Osteoblast-like cells with different embryologic origins behave differently in increasing zoledronic acid concentrations: a pilot study in pigs","volume":"123","author":"Kauffmann","year":"2017","journal-title":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology"},{"issue":"7","key":"10.1016\/j.bone.2026.117796_b97","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1002\/jcb.26728","article-title":"Cytoprotective effect of flavonoid-induced autophagy on bisphosphonate mediated cell death in osteoblast","volume":"119","author":"Kim","year":"2018","journal-title":"J. Cellular Biochemistry"},{"key":"10.1016\/j.bone.2026.117796_b98","doi-asserted-by":"crossref","DOI":"10.1186\/1746-160X-6-12","article-title":"The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro","author":"Koch","year":"2010","journal-title":"Head Face Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b99","doi-asserted-by":"crossref","DOI":"10.1186\/1746-160X-7-4","article-title":"The influence of bisphosphonates on human osteoblast migration and integrin aVb3\/tenascin C gene expression in vitro","volume":"7","author":"Koch","year":"2011","journal-title":"Head Face Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00784-010-0477-8","article-title":"Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro","volume":"16","author":"Koch","year":"2012","journal-title":"Clinical Oral Investigations"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bone.2026.117796_b102","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00198-013-2494-3","article-title":"Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss","volume":"25","author":"Lindtner","year":"2014","journal-title":"Osteoporosis International"},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b103","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jbm.a.36944","article-title":"Bisphosphonates inhibit surface-mediated osteogenesis","volume":"108","author":"Lotz","year":"2020","journal-title":"J. Biomedical Materials Research Part A"},{"issue":"3","key":"10.1016\/j.bone.2026.117796_b104","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/adj.12752","article-title":"The in vitro effect of VEGF receptor inhibition on primary alveolar osteoblast nodule formation","volume":"65","author":"McLaughlin","year":"2020","journal-title":"Australian Dental J."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b105","first-page":"869","article-title":"Protective effect of hypoxia on bisphosphonate-related bone cell damage","volume":"3","author":"Moon","year":"2010","journal-title":"Molecular Medicine Reports"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tripleo.2008.03.036","article-title":"The effects of bisphosphonates on osteoblasts in vitro","volume":"106","author":"Naidu","year":"2008","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontology"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b107","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10006-021-00982-8","article-title":"Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing","volume":"26","author":"Otto","year":"2022","journal-title":"Oral Maxillofacial Surgery-Heidelberg"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b108","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro","volume":"34","author":"Pan","year":"2004","journal-title":"BONE"},{"key":"10.1016\/j.bone.2026.117796_b109","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.archoralbio.2017.10.024","article-title":"Evaluation of the bisphosphonate effect on stem cells derived from jaw bone and long bone rabbit models: A pilot study","volume":"85","author":"Park","year":"2018","journal-title":"Archives Oral Biology"},{"issue":"9","key":"10.1016\/j.bone.2026.117796_b110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1600-0714.2012.01154.x","article-title":"Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition","volume":"41","author":"Patntirapong","year":"2012","journal-title":"J. Oral Pathology Medicine"},{"issue":"8","key":"10.1016\/j.bone.2026.117796_b111","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1302\/0301-620X.87B8.15446","article-title":"The effect of bisphosphonates and titanium particles on osteoblasts - An in vitro study","volume":"87","author":"Peter","year":"2005","journal-title":"J. Bone Joint Surgery-British Volume"},{"issue":"7","key":"10.1016\/j.bone.2026.117796_b112","first-page":"2713","article-title":"Combined effects of bisphosphonate and radiation on osteosarcoma cells","volume":"30","author":"Ryu","year":"2010","journal-title":"Anticancer Research"},{"issue":"10","key":"10.1016\/j.bone.2026.117796_b113","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1600-0714.2012.01173.x","article-title":"Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model","volume":"41","author":"Saracino","year":"2012","journal-title":"J. Oral Pathology Medicine"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020206","article-title":"Zoledronic acid modulation of TRPV1 channel currents in osteoblast cell line and native rat and mouse bone marrow-derived osteoblasts: Cell proliferation and mineralization effect","volume":"11","author":"Scala","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbrc.2005.09.198","article-title":"Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro","volume":"338","author":"Schindeler","year":"2005","journal-title":"Biochemical Biophysical Research Communications"},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00784-009-0312-2","article-title":"Expression profile and synthesis of different collagen types i, II, III, and v of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment","volume":"14","author":"Simon","year":"2010","journal-title":"Clinical Oral Investigations"},{"issue":"10","key":"10.1016\/j.bone.2026.117796_b117","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/jop.12944","article-title":"Impacts of platelet-rich fibrin and platelet-rich plasma on primary osteoblast adhesion onto titanium implants in a bisphosphonate in vitro model","volume":"48","author":"Steller","year":"2019","journal-title":"J. Oral. Pathol. Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117796_b118","first-page":"283","article-title":"Bone-related growth factors and zoledronic acid regulate the PTHrP\/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells","volume":"26","author":"Tenta","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bone.2026.117796_b119","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-2008-1078753","article-title":"Mechanisms of the Action of Zoledronic Acid on Human MG-63 Osteosarcoma Cells","volume":"40","author":"Tenta","year":"2008","journal-title":"Horm. Metab. Res."},{"issue":"34","key":"10.1016\/j.bone.2026.117796_b120","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1016\/j.biomaterials.2005.04.059","article-title":"Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells","volume":"26","author":"Von Knoch","year":"2005","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.bone.2026.117796_b121","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1601-0825.2010.01720.x","article-title":"Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro","volume":"17","author":"Walter","year":"2011","journal-title":"Oral Diseases"},{"key":"10.1016\/j.bone.2026.117796_b122","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/CCIDE.S259158","article-title":"Standardized Arrabidaea chica extract shows cytoprotective effects in zoledronic acid-treated fibroblasts and osteoblasts","volume":"12","author":"Wiziack Zago","year":"2020","journal-title":"Clinical Cosmetic Investigational Dentistry"},{"issue":"23","key":"10.1016\/j.bone.2026.117796_b123","article-title":"Influences of compressive force and zoledronic acid on osteoblast proliferation and differentiation: An in vitro study","volume":"11","author":"Yusa","year":"2021","journal-title":"Applied Sciences-Basel"},{"issue":"3","key":"10.1016\/j.bone.2026.117796_b124","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00784-014-1280-8","article-title":"Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts","volume":"19","author":"Zara","year":"2015","journal-title":"Clin. Oral Investig."},{"issue":"5","key":"10.1016\/j.bone.2026.117796_b125","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00784-017-2291-z","article-title":"Bisphosphonates hinder osteoblastic\/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells","volume":"22","author":"Zhang","year":"2018","journal-title":"Clinical Oral Investigations"},{"issue":"3","key":"10.1016\/j.bone.2026.117796_b126","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00223-023-01112-0","article-title":"Zoledronate promotes peri-implant osteogenesis in diabetic osteoporosis by the AMPK pathway","volume":"113","author":"Zhang","year":"2023","journal-title":"Calcified Tissue International"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:28:36Z","timestamp":1773898116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":126,"alternative-id":["S8756328226000220"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117796","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoblastic cell responses to zoledronate treatment in-vitro: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117796"}}